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ABSTRACT
Background and aims Rectal lesions traditionally repre-
sent the first lesions approached during endoscopic sub-
mucosal dissection (ESD) training in the West. We evaluat-
ed the safety and efficacy of rectal ESD in North America.
Methods This is a multicenter retrospective analysis of
rectal ESD between January 2010 and September 2018 in
15 centers. End points included: rates of en bloc resection,
R0 resection, adverse events, comparison of pre- and post-
ESD histology, and factors associated with failed resection.
Results In total, 171 patients (median age 63 years; 56%
men) underwent rectal ESD (median size 43mm). En bloc
resection was achieved in 141 cases (82.5%; 95%CI 76.8–
88.2), including 24 of 27 (88.9%) with prior failed endo-
scopic mucosal resection (EMR). R0 resection rate was
74.9% (95%CI 68.4–81.4). Post-ESD bleeding and perfora-
tion occurred in 4 (2.3%) and 7 (4.1%), respectively. Covert
submucosal invasive cancer (SMIC) was identified in 8.6% of
post-ESD specimens. There was one case (1/120; 0.8%) of
recurrence at a median follow-up of 31 weeks; IQR: 19–76
weeks). Older age and higher body mass index (BMI) were
predictors of failed R0 resection, whereas submucosal fi-
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Introduction
Endoscopic resection is the first-line treatment for mucosally
confined colorectal neoplasia given its associated lower cost,
morbidity, and mortality when compared to surgery [1, 2]. Var-
ious endoscopic resection techniques have been introduced
over the years, from conventional polypectomy to endoscopic
mucosal resection (EMR) and, more recently, endoscopic sub-
mucosal dissection (ESD). The European Society of Gastrointes-
tinal Endoscopy (ESGE) and the Japan Gastroenterological
Endoscopy Society (JGES) recommend ESD for colorectal le-
sions with suspected superficial submucosal invasion (SMI) or
for those that cannot be optimally removed en bloc by EMR [3,
4]. Furthermore, a recent American Gastroenterological Asso-
ciation (AGA) Clinical Practice Update has also endorsed ESD
for select colorectal lesions, including those at increased risk
for covert SMI [5].
However, the adoption of colorectal ESD in the USA and Ca-
nada has been limited due to its steep learning curve, higher
risk profile when compared to EMR, and differences in training
opportunities compared with Asia [6, 7]. Since early gastric can-
cer is rare in North America, rectal lesions have commonly be-
come the de facto first lesions approached during ESD training,
given the perceived lower technical difficulty of ESD in the rec-
tum when compared to other anatomical sites in the colon [6].
However, data from North America on clinical outcomes asso-
ciated with rectal ESD are lacking. This may be of particular im-
portance as a recent meta-analysis and systematic review indi-
cated a lower complete (R0) resection rate and higher risk for
postoperative bleeding after ESD in the rectum [8]. The aim of
this study was to evaluate the safety and efficacy of ESD for rec-
tal neoplasia across various centers in North America.
Methods
Study population
This is a retrospective multicenter cohort study of consecutive
patients ≥18 years of age undergoing rectal ESD at 15 centers
in the USA and Canada between January 2010 and September
2018. All patients provided informed consent for the proce-
dures. This study was approved by the institutional review
board for human research at each participating institution,
with the University of Florida serving as the central coordinat-
ing center.
Rectal lesions were defined as any lesion with an upper mar-
gin located within 18 cm of the anal verge and/or when more
than 50% of the lesion was situated within 15 cm from the anal
verge. Indications for ESD included nongranular-type laterally
spreading tumors (LST-NGs) of ≥20mm, granular-type (LST-
Gs) or mixed LST of ≥20–30mm, and lesions difficult to resect
with conventional EMR (i. e. lesions located near or at the den-
tate line, those with non-lifting sign, prior failed EMR) [3, 4]. We
excluded neuroendocrine tumors, gastrointestinal stromal tu-
mors, and patients with underlying inflammatory bowel dis-
ease and adenomatous polyposis. Data was collected from pro-
spectively maintained institutional endoscopic reporting data-
bases and by retrospective review of electronic medical re-
cords. The data obtained from all participating centers was
then compiled into a central database.
ESD procedure
Cases were performed with i. v. conscious sedation, deep seda-
tion or general anesthesia with endotracheal intubation, at the
discretion of the endoscopist and anesthesiologist (if involved).
Carbon dioxide was used for insufflation in all cases. With slight
variations, rectal ESD was performed as previously described
[3] (▶Fig. 1). Briefly, the procedures were performed with ei-
ther a single-channel gastroscope (GIF HQ190; Olympus Amer-
ica, Inc., Center Valley, PA, United States) or colonoscope (CF
H190AI or PCF H190L; Olympus America). Lesions were exam-
ined under high definition white light, near focus, and digital
or dye-based chromoendoscopy. Lesions were described ac-
cording to the Paris classification [9], and based on surface to-
pography (granular or non-granular lateral spreading tumors)
[10]. At the discretion of the endoscopist, the ESD knife tip
was used to demarcate the outer margin for the resection
area, approximately 5mm from the lesion. The submucosal
space was then expanded by injection of a lifting solution con-
taining Methylene Blue or Indigo Carmine admixed with normal
saline or with a viscous agent. The degree of submucosal fibro-
sis was determined based on the findings identified at the time
of ESD and classified as F0 (no fibrosis), F1 (mild fibrosis), or F2
(severe fibrosis) [11]. Rectal ESD was then achieved by repeated
cycles of injection and dissection with the electrocautery knife.
Cases of failed rectal ESD were treated with either conventional
EMR, hybrid ESD as defined by the JGES [3], or referred to sur-
gery. Upon completion of the ESD, endoscopic closure of the
resection bed using clips and/or endoscopic suturing was per-
formed at the discretion of the endoscopist.
Histopathology evaluation
All ESD resected tissue specimens were pinned down with nee-
dles onto cork after removal and fixed using 10% formalin solu-
tion. All specimens were stained with hematoxylin and eosin.
Histologic assessment was performed by pathologists from
each respective participating center according to the World
brosis was associated with a higher likelihood of both failed
en bloc and R0 resection.
Conclusion Rectal ESD in North America is safe and is
associated with high en bloc and R0 resection rates. The
presence of submucosal fibrosis was the main predictor of
failed en bloc and R0 resection. ESD can be considered for
select rectal lesions, and serves not only to establish a defi-
nitive tissue diagnosis but also to provide curative resection
for lesions with covert advanced disease.
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Health Organization classification of colorectal neoplasia and
the Vienna classification [12, 13].
ESD operator experience
All ESD procedures were performed by interventional endos-
copists from each participating center. All of the endoscopists
had long-standing experience in colorectal EMR, but varied in
their experience with ESD. Colon ESD experience was defined
as the total number of human colorectal ESD cases that each
endoscopist had performed by the time of study enrollment.
Novice and experienced colon ESD endoscopists were defined
as those with fewer or more than 10 colorectal ESDs by the
time of study participation, respectively.
Outcome measures and definitions
En bloc resection was defined as excision of the targeted lesion
in a single specimen. Complete histologic resection (R0) was
defined as resection with lateral and deep margins free of colo-
rectal neoplasia. Incomplete histological resection was defined
as failure to achieve neoplasia-free margins (R1), or when mar-
gins could not be adequately evaluated (Rx). Curative resection
was defined when all of the following criteria were met: (1) re-
sected specimen with negative lateral and deep margins of
colorectal neoplasia, (2) depth of SMI <1000µm below the
muscularis mucosae, (3) absence of poorly differentiated or
mucinous histology, and (4) absence of lymphovascular invol-
vement and tumor budding [3, 4]. A superficial invasive adeno-
carcinoma was defined as a lesion with SMI invasion <1000µm
below the muscularis mucosae. Recurrence referred to endo-
scopic and/or histological evidence of colorectal neoplasia at
follow-up. Adverse events were defined based on previously es-
tablished criteria by the American Society of Gastrointestinal
Endoscopy (ASGE) [14].
Statistical analysis
Descriptive statistics for each baseline variable was obtained
and expressed as mean and standard deviation (SD), or median
and interquartile ranges (IQR). Chi-squared or Fisher exact test
for categorical variables and the t test for continuous variables
were performed when indicated. Nominal P values are report-
ed; P values less than 0.05 were considered significant. Multiple
logistic regression analysis was performed to identify factors
associated with failed en bloc, R0 resection, and adverse
events. Specifically, for each of the dependent variables, we
conducted a backward model to select the optimal parsimo-
nious model for the data. We started with a full model by in-
cluding all of the observed baseline covariates and the least sig-
nificant independent covariate was removed from the model
until no more could be removed. All statistical analysis was per-
formed with the open source statistical software package R
(version 3.5.0).
Results
Baseline characteristics
A total of 171 patients (median age 63, IQR: 55–72.5 years;
55.6% men) underwent rectal ESD across 15 centers in the Uni-
ted States (n =14) and Canada (n =1) between January 2010
and September 2018 (▶Table 1). The median lesion size was
43mm (IQR: 34.8–60mm) and these were categorized accord-
ing to the Paris classification (▶Table1). A total of 104 lesions
(60.8%) were classified as lateral spreading granular tumors
(LST-G) and 38 (22.2%) as non-granular lesions (LST-NG). Most
of the lesions (142; 83%) had previously been manipulated be-
fore ESD: 130 (76%) were biopsied with forceps, 18 (10.5%) had
been tattooed, and 27 (15.8%) had a prior EMR attempt. Rectal
endoscopic ultrasound (EUS) was performed in 54/171 (31.6%)
before ESD. No pathological lymphadenopathy or invasion into
the muscularis propria was reported in any of the EUS. Baseline
histopathology (before ESD) was available in 151 out of 171
cases (▶Table 1). Among these, nine patients with invasive
adenocarcinoma (5.3%) were deemed poor surgical candidates
and thereby referred for ESD.
Procedural characteristics
Procedural characteristics are summarized in ▶Table2. The
median resected specimen size was 48mm (IQR: 35–65mm)
and located at a median of 4 cm (IQR: 1–8.3 cm) to 9.5 cm
(IQR: 6–14 cm) from the anal verge. Twenty-nine (17%) lesions
were located at the dentate line. Submucosal fibrosis was en-
▶ Fig. 1 Rectal ESD procedure. a A 35mm lesion (Paris classification 0-IIa + IIc) is identified in the rectum. b Post-ESD resection bed involving
nearly 50% of the circumference. c ESD en bloc resected specimen.
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▶ Table 1 Baseline characteristics.
Age, mean ± SD, years 63.4 ±11.7
Sex, n (%)
▪ Female 76 (44.4%)
▪ Male 95 (55.6%)
Body Mass Index; mean ± SD, kg/m2 28.2 ±6.2
ASA grade, n (%)
▪ I 23 (13.5%)
▪ II 82 (48%)
▪ III 53 (31%)
▪ IV 5 (2.9%)
▪ N/A 10 (5.8 %)
Lesion size, median (interquartile range), mm 43 (34.8–60)
Gross morphology, n (%)
▪ Lateral spreading granular tumor 104 (60.8%)
▪ Lateral spreading non-granular tumor 38 (22.2%)
▪ N/A 27 (15.8%)
Paris Classification, n (%)
▪ Ip 2 (1.2%)
▪ Is 15 (8.8 %)
▪ 0–IIa 45 (26.3%)
▪ 0–IIb 7 (4.1%)
▪ 0–IIc 1 (0.6%)
▪ 0–III 0
▪ IIa + IIc 29 (17%)
▪ IIc + IIa 2 (1.2%)
▪ IIa + Is 33 (19.3%)
Lesion manipulation before ESD, n (%)
▪ None 29 (17%)
▪ Tattoo at the lesion 18 (10.5%)
▪ Cold biopsy forceps 130 (76)
▪ Hot biopsy forceps 5 (2.9)
▪ Failed endoscopic mucosal resection (EMR) 27 (15.8)
▪ Endoscopic ablation 4 (2.3)
Pre-ESD histopathology, n (%)
▪ Adenoma with LGD 87 (50.9)
▪ Adenoma with HGD 52 (30.4)
▪ Sessile serrated adenoma/polyp 3 (1.8)
▪ Invasive adenocarcinoma 9 (5.3)
▪ Not available 20 (11.7)
ASA, American Society of Anesthesiologists; SD, standard deviation; ESD,
endoscopic submucosal dissection; LGD, low grade dysplasia; HGD, high
grade dysplasia.
▶ Table 2 Procedural characteristics.
Type of anesthesia
▪ Conscious sedation 37 (21.6%)
▪ Monitored anesthesia care 92 (53.8%)
▪ General anesthesia 42 (24.6%)
Size of resected specimen; median (interquartile
range), mm
48 (35–65)
Lesion location; median (interquartile range), mm
▪ Distance of distal lesion margin from dentate
line
4 (1–8.3)
▪ Distance of proximal lesion margin from dentate
line
9.5 (6–14)
Degree of submucosal fibrosis, n (%)
▪ F0 (none) 76 (44.4%)
▪ F1 (mild) 43 (25.1%)
▪ F2 (severe) 52 (30.4%)
Total procedure time; median (interquartile
range), min
120 (80–176)
Type of ESD knife used, n (%)
▪ Dual knife 116 (67.8%)
▪ Hybrid knife 56 (32.7%)
▪ IT-knife 45 (26.3%)
▪ Combination of ESD knives 43 (25.1)
Epinephrine added to submucosal injection, n (%)
▪ Yes 77 (45%)
▪ No 94 (55%)
Elective endoscopic closure of post-ESD site, n (%)
▪ Yes 58 (33.9%)
▪ No 113 (66.1%)
Hospitalization following ESD, n (%)
▪ Yes 74 (43.3%)
▪ No 97 (56.7%)
ESD histopathology, n (%)
▪ Adenoma with LGD 85 (49.7%)
▪ Adenoma with HGD 63 (36.8%)
▪ Sessile serrated adenoma/polyp 3 (1.8%)
▪ Invasive adenocarcinoma 20 (11.7%)
ESD, endoscopic submucosal dissection; LGD, low grade dysplasia; HGD,
high grade dysplasia.
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countered in most lesions (95; 55.6%), of which 43 (25.1%) and
52 (30.4%) were categorized as mild (F1) and severe (F2),
respectively. The median procedure time was 120 minutes
(IQR: 80–176 minutes). Overall, the Dual Knife (Olympus Amer-
ica) was the most commonly used electrocautery ESD knife
(116; 67.8%), followed by the Hybrid Knife (ERBE USA, Mariet-
ta, GA, United States) (56; 32.7%) and IT-nano knife (Olympus
America) (45; 26.3%). Elective closure of the ESD resection site
was performed in 58 of 171 cases (33.9%) using endoscopic
clips (26; 15.2%), suturing (27; 15.8%) or a combination there-
of (5; 2.9%). Most cases (97/171; 56.7%) were performed in the
outpatient setting. The mean post-procedural hospitalization
stay was 0.5±0.7 days. Final histopathology of the ESD resect-
ed specimens is shown in ▶Table2.
Resection outcomes and adverse events
Overall en bloc resection was achieved in 141 out of 171 cases
(82.5%; 95%CI 76.8–88.2), in 24 out of 27 rectal lesions
(88.9 %) with previously failed EMR, and in 93.1% (27/29) of
those located at the dentate line. En bloc resection rate was
lower (72.2%) in those with a tattoo at the lesion (13/18). Hy-
brid ESD (23/30; 76.7%) or piecemeal EMR (7/30; 23.3%) was
performed when conventional ESD failed. R0 (complete) resec-
tion was achieved in 128 of 171 cases (74.9%; 95%CI 68.4–
81.4). R1 resections were due to positive lateral margins (n =
13), deep margins (n =4), both (n =3), or uncertain (Rx) mar-
gins (n =23). The overall curative resection rate was 73.1%
(95%CI 66.5–79.8).
There were 20 patients with invasive adenocarcinoma on fi-
nal pathology. Curative resection was achieved in 9 out of 11
cases (81.8%) of superficially invasive adenocarcinoma, with
the two non-curative resection cases due to positive lateral
margins. Of these, one patient underwent surgery with no resi-
dual disease whereas the other one declined treatment. ESD
was non-curative for the remaining nine cases of invasive ade-
nocarcinoma due to: poorly differentiated histology (n =3),
lymphovascular involvement (n=4), and/or submucosal inva-
sion >1000µm (n=3). Two of these patients underwent sur-
gery with no residual tumor or lymph node metastases in the
resected specimens. The remaining seven patients were either
unfit or declined additional treatment.
In all, there were 20 adverse events (11.7%; 95%CI 7.7–17.4)
reported (▶Table3). There were three cases (1.8%) of early
bleeding (< 24 hours after ESD) and one case (0.6%) of delayed
bleeding on postoperative day #5 upon antithrombotic therapy
resumption. All cases of bleeding responded to endoscopic
therapy. Perforation occurred in seven cases (4.1%): 4 were
closed endoscopically, 2 were managed expectantly with full
recovery and one patient was referred for full-thickness transa-
nal resection. The patient who underwent full-thickness transa-
nal resection had invasive adenocarcinoma on baseline histopa-
thology and had elected ESD over surgery based on personal
preference and comorbidities. The perforation was deemed dif-
ficult to repair endoscopically, and upon discussion with colo-
rectal surgery, the decision was to proceed with full-thickness
transanal resection. Five patients (2.9%) reported nausea and/
or abdominal pain, all adequately managed with anti-emetics
and analgesics. Urinary retention in three (1.8%) patients re-
solved with short-term catheterization. An anal stricture devel-
oped in one patient after ESD of a nearly circumferential 70mm
adenoma with high grade dysplasia located 4 cm from the den-
tate line. The stricture responded to one session of endoscopic
dilation.
Comparison of pre- and post-ESD histopathology:
covert invasive adenocarcinoma
Tissue diagnosis was obtained for baseline histopathology in
151 of the 171 cases referred for ESD. Overall, the pre- and
post-ESD histology matched in 80.1% (121/151) and was up-
staged in 23 (15.2%) of the 151 cases. Ten adenomas (9.2%)
with low grade dysplasia were upstaged to high grade dyspla-
sia. Similarly, 13 (8.6%) dysplastic lesions (11 HGD and 2 LGD)
were upstaged to invasive adenocarcinomas on final histopa-
thology. Conversely, seven lesions (4.6%) were downstaged
from invasive adenocarcinoma to high grade dysplasia (n =2),
and from high grade to low grade dysplasia (n=5).
Follow-up
A total of 120 out of the 171 patients (70.2%) underwent sur-
veillance endoscopy at a median of 23 weeks (IQR: 12–24
weeks) after ESD. None of the patients had undergone sur-
gery at the time of surveillance endoscopy. The remaining 51
patients (29.8%) were lost to follow-up. There was one case
(1/120; 0.8%) of recurrence on follow-up (median 31 weeks;
IQR: 19–76 weeks). This patient had initial curative resection
for a well-differentiated adenocarcinoma with superficial SMI
▶ Table 3 Resection outcomes of rectal ESD.
Overall en bloc resection rate, n (%) 141 (82.5%)
En bloc resection rate in complex lesions, n (%)
▪ Previously failed EMR (n=27) 24 (88.9%)
▪ Lesions at the dentate line (n =29) 27 (93.1%)
▪ Tattoo at the lesion (n = 18) 13 (72.2%)
R0 resection, n (%) 128 (74.9%)
R1 resection, n (%) 20 (11.7%)
Rx resection, n (%) 23 (13.5%)
Overall curative resection, n (%) 125 (73.1%)
Curative resection for superficial invasive adenocar-
cinoma (n =11) , n (%)
9 (81.8%)
Adverse events, n (%)
▪ Bleeding 4 (2.3%)
▪ Perforation 7 (4.1%)
▪ Nausea/abdominal pain 3 (2.9%)
▪ Postoperative urinary retention 3 (1.8%)
▪ Post-ESD anal stricture 1 (0.6%)
EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissec-
tion.
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and no lymphovascular involvement. Repeat biopsies on sur-
veillance confirmed invasive adenocarcinoma. Further treat-
ment was not pursued given the patient’s advanced age and
comorbidities.
Endoscopist experience
The procedures were performed by endoscopists with varied
colon ESD experience (▶Table 4). The overall endoscopists’me-
dian colon ESD experience was 1 (IQR: 0.5–3.5). Most (14/15) of
the providers were considered novice ESD endoscopists (< 10
colon ESDs) at the time of study participation. One endoscopist
(study center #1) was highly experienced in colon ESD, having
previously performed 350 colorectal ESDs. The en bloc resec-
tion and adverse event rates for each participating center are
shown in ▶Table 4. There was no statistically significant differ-
ence between the overall en bloc resection rate and that among
novice endoscopists (82.5%; 95%CI 76.8–88.2 vs. 77.1%; 95%CI
68.8–83.8; P=0.31) nor in the adverse event rates (11.7%; 95%
CI 7.7–17.4 vs. 14.3%; 95%CI 8.3–23.2; P=0.57).
Predictors of treatment outcomes and adverse
events
A multivariate logistic regression was performed to identify
predictors of failed en bloc and R0 resection (▶Table 5). We in-
cluded age, gender, body mass index (BMI), American Society
of Anesthesiologists (ASA) grade, lesion size, morphology
(LST-G vs LST-NG), location (distance from the dentate line),
prior EMR attempted (yes vs. no), presence of submucosal fi-
brosis, and endoscopist colorectal ESD experience as covari-
ates.
Mild (F1) submucosal fibrosis was a predictor for en bloc re-
section failure (OR 30.65; 95%CI 2.244–1105; P=0.023),
whereas severe (F2) submucosal fibrosis was a strong predictor
of both failed en bloc (OR: 166.5; 95%CI 12.21–8719; P=0.002)
and R0 resection (OR: 21.86; 95%CI 2.466–3365; P=0.012).
Both increasing age and BMI were associated with significantly
higher odds of R0 resection failure (▶Table 5). Lesion size, mor-
phology, location, prior EMR attempts, and endoscopist experi-
ence were not predictive of en bloc or R0 resection failure.
There were no significant factors predictive of adverse events
(▶Table 5).
Discussion
This is the first multicenter study from North America reporting
clinical outcomes of ESD for rectal neoplasia. Although EMR re-
mains the first-line treatment for most non-malignant colorec-
tal lesions in North America, ESD has gain acceptance for select
lesions, as supported by a recent AGA Clinical Practice Update
[5]. The main limitation of EMR is the piecemeal nature of the
resection when involving lesions larger than 20mm, which lim-
its accurate histopathological evaluation and is associated with
a higher recurrence rate [7, 15–17]. In this study, en bloc and
R0 resection with ESD was achieved in 82.5% and 74.9% of the
lesions, respectively, which is comparable with data originating
from Europe [8]. Furthermore, on follow-up at a median of 31
weeks, recurrence was detected in only one patient (0.9%)
which is on par with the very low recurrence rate consistently
demonstrated after ESD [18, 19].
EMR can be technically challenging in lesions with extensive
submucosal fibrosis or in difficult locations [20, 21]. Our data
demonstrates that ESD was quite successful in difficult-to-treat
rectal neoplasia. Most of the lesions (55.5%) in this study were
complicated by submucosal fibrosis, yet en bloc resection with
ESD was still achieved in most of these difficult cases (70/95;
73.7%). Furthermore, ESD also permitted en bloc resection of
nearly all lesions located at the dentate line (93.1%) or those
with prior failed EMR (88.9%). The efficacy of ESD in these chal-
lenging scenarios should not be understated, as failed endo-
scopic resection can incur (1) additional costs, (2) a potential
risk of progression from under-recognition of residual/recur-
rent neoplasia following piecemeal resection, and (3) the bur-
den of repeated invasive measures. In all, ESD can be consid-
ered to be a first-line or salvage therapy in difficult-to-resect
rectal neoplasia, which is concordant with current Japanese
and European guidelines, and the recent AGA Update [3–5].
Accurate pretreatment oncological staging is crucial in di-
recting patient care. Nevertheless, despite our best efforts,
neoplastic lesions in the rectum are often either under- or over-
staged [22–27]. In our study, there were 13 cases (8.6%) of cov-
ert invasive adenocarcinoma on final ESD histopathology. ESD
was curative in 81.8% of invasive adenocarcinomas with super-
ficial SMI and favorable histologic features. Conversely, piece-
meal resection with EMR would have potentially subjected all
of these patients to unwarranted surgery. Hence, en bloc resec-
▶ Table 4 Endoscopist experience per center and ESD outcomes.
Study
center
Colon
ESD ex-
perience
# Cases
in study
En bloc
resection
rate, n (%)
Adverse
event rate,
n (%)
1 350 40 40 (100) 2 (5)
2 8 6 6 (100) 1 (16.7)
3 2 4 1 (25) 1 (25)
4 0 3 3 (100) 0 (0)
5 0 33 29 (87.9) 4 (12.1)
6 1 4 2 (50) 0 (0)
7 1 9 6 (66.7) 1 (11.1)
8 1 5 5 (100) 0 (0)
9 1 10 5 (50) 1 (10)
10 0 12 10 (83.3) 2 (16.7)
11 5 8 5 (62.5) 0 (0)
12 1 10 8 (80) 2 (20)
13 0 8 5 (62.5) 2 (25)
14 2 8 7 (87.5) 2 (25)
15 5 11 9 (81.8) 2 (18.2)
ESD, endoscopic submucosal dissection.
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▶ Table 5 Predictors of failed en bloc resection, failed R0 resection and adverse events.
Variable OR 95%CI P value
Failed en bloc resection
Age 1.106 (0.992, 1.232) 0.069
Lesion size 0.997 (0.949, 1.043) 0.903
Morphology (LST-G vs LST-NG) 0.857 (0.112, 7.566) 0.881
At dentate line (yes vs. no) 1.229 (0.965, 1.718) 0.139
Prior EMR attempt (yes vs no) 4.469 (0.372, 89.02) 0.267
Colonic ESD experience 1.025 (0.873, 1.134) 0.608
Submucosal fibrosis
▪ F1 30.65 (2.244, 1105) 0.023
▪ F2 166.5 (12.21, 8719) 0.002
Failed R0 resection
Age 1.104 (1.021, 1.216) 0.023
BMI 1.191 (1.042, 1.414) 0.022
ASA grade
▪ 2 4.567 (0.226, 257.5) 0.370
▪ 3 13.64 (0.486, 1089) 0.160
▪ 4 0.000 (0.000, 2e +59) 0.993
Lesion size 1.023 (0.975, 1.073) 0.332
Morphology (LST-G vs LST-NG) 1.266 (0.206, 9.103) 0.802
At dentate line (yes vs no) 1.170 (0.927, 1.532) 0.207
Prior EMR attempt (yes vs no) 5.566 (0.435, 90.23) 0.190
Colonic ESD experience 1.025 (0.953, 1.119) 0.536
Submucosal fibrosis
▪ F1 2.417 (0.268, 22.44) 0.421
▪ F2 21.86 (2.466, 3.365) 0.012
Adverse events
Age 1.145 (0.996, 1.391) 0.096
Male 2.585 (0.314, 25.80) 0.385
BMI 1.036 (0.872, 1.229) 0.666
ASA grade
▪ 2 1.055 (0.049, 30.81) 0.973
▪ 3 0.310 (0.003, 21.48) 0.585
▪ 4 0.000 (0.000, 2e +258) 0.998
Lesion size 0.981 (0.921, 1.039) 0.510
Morphology (LST-G vs LST-NG) 0.486 (0.050, 4.003) 0.501
At dentate line (yes vs no) 0.691 (0.389, 0.995) 0.105
Prior EMR attempt (yes vs no) 141.5 (0.540, 37032) 0.081
Colonic ESD experience 1.048 (0.948, 1.197) 0.397
Submucosal fibrosis
▪ F1 0.000 (0.000, 1.6e +96) 0.995
▪ F2 4.465 (0.261, 136.6) 0.321
ASA, American Society of Anesthesiologists; BMI, Body Mass Index; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection. LST-G, laterally
spreading tumor, granular type; LST-NG. laterally spreading tumor, non-granular type.
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tion is of particular importance for curative resection of lesions
with suspected SMI, including large LST lesions with unsuspec-
ted advanced histopathology. And while ESD may be non-cura-
tive in some cases of invasive adenocarcinoma, prior data indi-
cate that non-curative ESD does not compromise future at-
tempts at surgery [25]. Similar to prior reports on gastric neo-
plasia, our study demonstrated that histologic discordance be-
tween forceps biopsy and ESD is not uncommon. Factors asso-
ciated with downgrade compared to upgrade histology have in-
cluded smaller tumor size and a lower number of biopsy speci-
mens, further highlighting the limitations of establishing a diag-
nosis with forceps biopsies [28, 29]. Hence, when pretreatment
diagnosis is uncertain or fails to identify advanced disease, ESD
may prove to be an accurate staging procedure to guide subse-
quent management.
The transition to colorectal ESD in North America has been
slower than its adoption in Asia and Europe, particularly due to
the concern for serious adverse events. In our study, ESD was
associated with an adequate safety profile, even though nearly
all of our endoscopists had limited (less than 10) colon ESD ex-
perience before this study. It should be important to highlight
that most cases of perforation (5/7; 71.4%) occurred in lesions
with submucosal fibrosis. Given that severe submucosal fibrosis
was a predictor for both failed en bloc and R0 resection, we
suggest that ESD trainees should avoid lesions with suspected
submucosal fibrosis in the earlier stages of their training. Fur-
thermore, increasing BMI was also associated with a significant-
ly higher odds of R0 resection failure. Patients are often reposi-
tioned during ESD to optimize visualization during dissection
and to maximize traction force with the use of gravity. We spec-
ulate that patient positioning may be more challenging and
performed less frequently in obese patients, thereby account-
ing for the lower R0 resection rates in this subgroup. In this
study, most ESD cases were performed in the outpatient set-
ting, suggesting that hospitalization may not be routinely re-
quired, thereby limiting procedure-related costs. Given the
steep learning curve, ESD of large complex colorectal polyps
should be reserved to high-volume specialized centers. Future
long-term prospective studies are needed to better define not
only the role of ESD in the rectum but also for the treatment of
lesions in the rest of the colon.
We acknowledge the limitations of this study. The study was
retrospective and limited by its uncontrolled design and inher-
ent selection bias. All ESD cases were performed by endos-
copists trained in advanced endoscopic resection techniques;
thus, results may not be generalizable. Furthermore, differen-
ces in ESD training background among the participating endos-
copists may have led to performance variability. Nonetheless,
with the exception of one provider, most of our endoscopists
were novices in colon ESD and our results included all consecu-
tive cases during this initial phase, thereby providing a more
realistic and accurate picture on the current status of rectal
ESD in North America.
We also recognize that, in the absence of central pathology
review, discrepancies in diagnosis and staging of lesions be-
tween centers could have affected our results. Another signifi-
cant limitation is that nearly one-third of the patients did not
undergo surveillance (lost to follow-up) and the relatively short
follow-up prohibits significant conclusions on long-term out-
comes. Furthermore, in the absence of a pre-specified follow-
up protocol, it is possible that delayed adverse events could
have been missed and underestimated in our analysis. In addi-
tion, while this is one of the largest studies on rectal ESD, the
relatively small sample size may have impeded finding statisti-
cally significant differences in outcomes among the three train-
ing phases. Lastly, the lack of comparison to alternative meth-
ods, such as piecemeal EMR, limits conclusions on the role of
colorectal ESD.
In summary, our study demonstrates that rectal ESD in
North America is safe and associated with high resection rates,
even in difficult lesions. ESD should be considered for select
rectal lesions, particularly those with possible SMI, as it can
serve as an oncologic staging tool and is curative for superficial-
ly invasive covert advanced disease.
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